Assay Development & Screening (Key Capabilities)
Assay Development

• Development of fluorescent-based cellular, biochemical, radiochemical and LC-MS assays carried out by an experienced team of scientists
• Proven expertise in the adaptation and miniaturisation of client assays
• Labelling chemistry, protein and cell production performed in an integrated fashion to increase efficiency

Medium and High Throughput Screening

• EVOscreen™: HTS conducted in miniaturised 384, 1536 and 2080 well formats on three proprietary and fully integrated screening systems using our Insight™ single molecule reader
• A+: Proprietary software designed to track the entire process from raw screening to final data analysis and summary reports ensuring rapid and reliable data provision
• Functional assays available in multiple formats including FLIPR® assay systems

Screening Library

• High quality library consisting of 250,000 compounds for HTS, selected for diversity as well as optimised for gene family focus

High Content Screening

• Opera™: State-of-the-art proprietary cellular imaging used for detailed intracellular analysis and pathway screening
• Multiplexing capability with the distinct benefit of simultaneously measuring target activity and cytotoxicity / apoptosis

Compound Profiling (incl. Secondary Assays)

• Experience in identifying and implementing screening strategy against related targets
• High Throughput Fragment Screening
• FCS+plus: Proprietary readout technology providing fast and accurate identification of active fragments
• Library containing 20,000 carefully selected fragments

Compound Libraries (Key Capabilities)
Library Design

• Structure and ligand-based design strategies carried out by an experienced team of molecular modellers
• Proprietary software used to design libraries for maximum diversity or targeted against specific gene families such as GPCR's, kinases and ion channels whilst ensuring favourable drug-like or lead-like criteria are met
• EVOseek™: Software written by Evotec, used for in silico prediction of ADMET properties for compound libraries

Library Synthesis

• Latest technologies tested and implemented resulting in the effective and efficient synthesis of high quality custom libraries
• Extensive range of validated chemistries applied to ensure tractable synthesis of analogues and hits
• New reaction types validated giving access to novel templates
• Design-of-experiments methodology employed routinely to achieve effective reaction optimisation

Compound Management

• State-of-the-art high throughput analytical and purification platform using LC-MS MUX technology, applied to rapidly analyse and enhance our clients' compound libraries
• Dedicated reformatting team ensuring all plate, tube and vial formats are supported
• Computational chemistry selection of compounds from internal chemistries and commercial sources used to enhance diversity or provide target class focus for screening collections

Medicinal Chemistry (Key Capabilities)
Structural Biology

• Expertise in de novo X-ray crystallographic structure elucidation facilitating novel structural information for rational compound design
• Routine and effective delivery of atomic structure information of bound ligands to drug targets, maximising the efficiency of synthetic chemistry through structure-driven drug discovery

Target Class Expertise

• Significant biology and chemistry expertise in all major target classes resulting in more than 100 patent applications with Evotec scientists as named inventors
• Efficient and successful drug discovery via an unrivalled range of solutions from ligand design to delivery of clinical candidates

Hit to Lead & Lead Optimisation

• Hit to lead projects conducted in a rigorous and efficient manner, involving hit-confirmation and validation followed by rapid optimisation
• Highly skilled and experienced medicinal chemists making use of a hypothesis-driven, multiparameter approach to lead optimisation

Computational Chemistry

• Computational and medicinal chemists working closely together applying ligand and structure-based methods, ensuring the effective design of new analogues based on existing or alternative scaffolds
• QSAR and in silico ADMET models developed for each project and used in our hypothesis-driven, multiparameter optimisation process

Pharmacokinetics

• Comprehensive range of high quality in vitro ADMET assays used to reduce the attrition rate within preclinical and clinical testing
• Integration of pharmacokinetic and pharmacodynamic information to accelerate lead optimisation programmes for all target classes

Primary & Secondary Screening Support

• Experienced teams of biologists and medicinal chemists working together, enabling the efficient generation, analysis and optimisation of SAR information
• Selectivity and functional assays to maximise SAR information and ensure rapid progression of your programme

Chemical & Pharmaceutical Development (Key Capabilities)
Custom Preparation

• Lab-scale cGMP and non-GMP custom synthesis
• Access to sophisticated and wide ranging chemistries

Process Research & Development (PRD)

• PRD services to reduce the number and complexity of the chemical synthetic steps
• Development of processes suitable for large scale manufacture
• Route development

Analytical Development & Testing

• Full analytical services for IND/NDA
• - Method development
• - Method validation
• - Stability studies

Pre-Formulation Package

• Full range of pharmaceutical services including salt selection, polymorphism studies and pre-formulation testing
• Identification of the appropriate formulation strategy for the drug candidate

Pilot Plant

• Clinical trial material of up to several hundred kilos can be manufactured to support Phase I - III clinical trials
• Manufacture of commercial supply material as well as non cGMP material for toxicity studies
• FDA and MHRA inspected pilot plants
• Certified to ISO14001 environmental quality standard
• Provision of CMC sections to support both IND/CTA and NDA/MAA submissions

Drug Formulation & Manufacture

• Expertise in developing liquid or lyophilised formulations for small molecules and biologicals including proteins, peptides, and antibodies
• Manufacture of liquid or lyophilised aseptic batches of small molecules and biologicals for clinical trials, including cytotoxics
• In house Qualified Person (QP) release of clinical trial materials